Table 3 Combination therapy related AEs and perioperative complications
Adverse events | Vp3 (N = 22) n (%) | Vp4 (N = 18) n (%) | p value |
|---|---|---|---|
Combination therapy related AEs | |||
All AEs, yes | 19 (86.4) | 18 (100) | 0.253 |
Grade 3 AEs | 0.486 | ||
Hypertension | 5 (22.7) | 2 (11.1) | |
GGT increased | 1 (4.5) | 2 (11.1) | |
Liver autoimmune disorder | 0 (0.0) | 1 (5.6) | |
Blood bilirubin increased | 0 (0.0) | 1 (5.6) | |
Platelet count decreased | 0 (0.0) | 1 (5.6) | |
Abdominal pain | 0 (0.0) | 1 (5.6) | |
Myocarditis | 1 (4.5) | 0 (0.0) | |
Fever | 0 (0.0) | 1 (5.6) | |
Perioperative complications | |||
Clavien-Dindo score | 0.613 | ||
No or I or II | 18 (81.8) | 17 (94.4) | |
IIIa | 3 (13.6) | 1 (5.6) | |
IV | 1 (4.5) | 0 (0.0) | |
PVT classification | 0.439 | ||
No PVT | 21 (95.5%) | 15 (83.3%) | |
Grade 1 | 0 (0.0) | 2 (11.1%) | |
Grade 2 | 1 (4.5%) | 1 (5.6%) | |
Long-term portal vein patency, yes | 21(95.5) | 17(94.4) | 0.704 |